The Ordinary Salicylic Acid 2% Solution: a four-pass review

The manufacturer describes this product as a water-based serum for acne-prone skin. Its direct US ingredient panel identifies salicylic acid 2% as the acne-treatment active. Those details are specific enough to distinguish it from a wash, but they do not make it a cream or equate it with a compounded prescription preparation. US product record.

The cream-and-alternatives comparison preserves those distinctions. A format description tells readers what record they are looking at. It does not establish a fixed ranking for irritation, effectiveness or the needs of a particular person, and this review does not derive an application plan from the format.

The published inactive list includes water, glycerin, pentylene glycol, chlorphenesin, phenoxyethanol and other components. These belong to the identity of the finished solution even though the headline highlights one active. Calling the other ingredients inactive does not make the complete formula irrelevant to a question about a product. Current ingredient panel.

The brand says its formulations can change and that the list online may differ from the box according to when and where it was purchased. We therefore do not assume an earlier review describes every current bottle. The label-version guide explains why a dated page and a specific package are different pieces of evidence.

AAD identifies salicylic acid as an ingredient used for acne, with particular relevance to blackheads and whiteheads. That helps explain its appearance in the product's acne-treatment panel. The source does not establish this solution's performance against Pore Favor, identify a reader's condition or validate every claim about texture on the seller's page. AAD adult-acne context.

The brand describes an updated formulation made with salicylic acid in powder form and enhanced texture. Those are manufacturer statements, not an independently established superiority result. A favorable formulation description is insufficient to reconstruct study methods, a control group or the probability of improvement for another person.

The page warns that dryness and irritation become more likely when another topical acne medication is also used. Its FAQ adds product-specific cautions involving other acids, retinoids and peptides. We report the scope of that wording rather than turn it into a universal compatibility chart for entire ingredient families. Manufacturer warnings.

AAD also discusses moisturizers within acne care because salicylic acid and other treatments can dry or irritate skin. This does not prove that a particular additional product will resolve an individual's discomfort. Our matching-percentage guide avoids assuming equal tolerance among preparations just because their active panels contain the same number. AAD moisturizer context.

Fresh US product metadata identifies a 30 mL variant with a displayed promotional price of $6.03. The visible page shows $6.70 as the price from which it has been reduced. Neither number establishes a future offer or the complete cost of an untested checkout. Shipping and other applicable order conditions need their own record. Current bottle offer.

A bottle is also not a verified month of treatment. The amount someone would actually receive can be documented, while how long it would last in an individual plan remains unknown here. The supply-cost guide shows why duration should not be invented to make a bottle compare neatly with a term-based offer.

The site's Usage Details and FAQ are not aligned in their application-frequency wording. Separate consumer sensitivity-check descriptions also appear. We do not choose a passage, reproduce a timetable or combine them into new advice. The precise package instructions and clarification from the manufacturer or an appropriate professional are needed where uncertainty matters. Website wording.

FDA explains the functions of the Drug Facts fields, including warnings and directions, and notes that product labels can change. That is a reason to retain the actual record, rather than rely on a review's memory of it. FDA label explanation.

The public material establishes the named solution, its advertised active, a current ingredient list and an observed bottle price. It also reveals questions that a simpler product summary might miss. None of those findings amount to testing the serum or knowing how an individual's skin would respond.

The Pore Favor review and CeraVe labeling review document different gaps in different formats. Comparing those records can sharpen a professional question about the exact preparation. It cannot establish interchangeability, supply a personal routine or substitute a commercial preference for the assessment of an ongoing skin concern.